Top

Published in:

01-11-2010

Periodic Fever Syndromes

Authors: Zachary Jacobs, Christina E. Ciaccio

Published in: Current Allergy and Asthma Reports | Issue 6/2010

Abstract

The periodic syndromes represent a heterogeneous group of disorders that can be very difficult for practicing physicians to diagnosis and treat. This article presents an orderly approach to hyperimmunoglobulin D syndrome; tumor necrosis factor receptor-1 periodic syndrome; familial Mediterranean fever; periodic fever with aphthous stomatitis, pharyngitis, and adenitis syndrome; and cryopyrin-associated periodic syndromes by highlighting the disease presentation, diagnosis, pathogenesis, and treatment. Recent advances are also discussed.

Drenth JP, Haagsma CJ, van der Meer JW: Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine 1994, 73:133–144.CrossRefPubMed

Drenth JP, Cuisset L, Grateau G, et al.: Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 1999, 22:178–181.CrossRefPubMed

Houten SM, Frenkel J, Rijkers GT, et al.: Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet 2002, 11:3115–3124.CrossRefPubMed

Haraldsson A, Weemaes CM, Jonasdottir S, et al.: Serum immunoglobulin D in infants and children. Scand J Immunol 2000, 51:415–418.CrossRefPubMed

Mandey SH, Schneiders MS, Koster J, Waterham HR: Mutational spectrum and genotype-phenotype correlations in mevalonate kinase deficiency. Hum Mutat 2006, 27:796–802.CrossRefPubMed

Simon A, Drewe E, van der Meer JW, et al.: Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004, 75:476–483.CrossRefPubMed

Attout H, Guez S, Ranaivo I, et al.: A patient with hyper-IgD syndrome responding to simvastatin treatment. Eur J Intern Med 2008, 19:e82–e83.CrossRefPubMed

Arkwright PD, McDermott MF, Houten SM, et al.: Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol 2002, 130:484–488.CrossRefPubMed

Rigante D, Ansuini V, Bertoni B, et al.: Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int 2006, 27:97–100.CrossRefPubMed

10.

Naruto T, Nakagishi Y, Mori M, et al.: Hyper-IgD syndrome with novel mutation in a Japanese girl. Mod Rheumatol 2009, 19:96–99.CrossRefPubMed

11.

Sornsakrin M, Wenner K, Ganschow R: B cell cytopenia in two brothers with hyper-IgD and periodic fever syndrome. Eur J Pediatr 2009, 168:825–831.CrossRefPubMed

12.

Hull KM, Drewe E, Aksentijevich I, et al.: The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002, 81:349–368.CrossRef

13.

Mulley J, Saar K, Hewitt G, et al.: Gene localization for an autosomal dominant familial periodic fever to 12p13. Am J Hum Genet 1998, 62:884–889.CrossRefPubMed

14.

Nedjai B, Hitman GA, Yousaf N, et al.: Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008, 58:273–283.CrossRefPubMed

15.

Stojanov S, Kastner DL: Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005, 17:586–599.CrossRefPubMed

16.

Drewe E, Huggins ML, Morgan AG, et al.: Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 2004, 43:1405–1408.CrossRef

17.

• Gattorno M, Pelagatti MA, Meini A, et al.: Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008, 58:1516–1520. In this paper, five patients with confirmed TRAPS were treated successfully with anakinra, showing a prompt response and resolution of symptoms. During the next several months, while treatment was continued, there were no episodes of fever or other clinical manifestations of the disease.CrossRefPubMed

18.

Nedjai B, Hitman GA, Quillinan N, et al.: Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2009, 60:619–625.CrossRefPubMed

19.

Ben-Chetrit E, Levy M: Familial Mediterranean fever. Lancet 1998, 351:659–664.

20.

Tidow N, Chen X, Muller C, et al.: Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. Blood 2000, 95:1451–1455.PubMed

21.

Samuels J, Aksentijevich I, Torosyan Y, et al.: Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 1998, 77:268–297.CrossRef

22.

Yalcinkaya F, Ozen S, Ozcakar ZB, et al.: A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 2009, 48:395–398.CrossRef

23.

Ben-Chetrit E, Levy M: Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum 1991, 20:241–246.CrossRefPubMed

24.

Lidar M, Scherrmann JM, Shinar Y, et al.: Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 2004, 33:273–282.CrossRefPubMed

25.

Tunca M, Akar S, Soyturk M, et al.: The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: a double-blind, placebo-controlled trial. Clin Exp Rheumatol 2004, 22:S37–S40.PubMed

26.

Calligaris L, Marchetti F, Tommasini A, Ventura A: The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 2008, 167:695–696.CrossRefPubMed

27.

Moser C, Pohl G, Haslinger I, et al.: Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol Dial Transplant 2009, 24:676–678.CrossRefPubMed

28.

Padeh S, Brezniak N, Zemer D, et al.: Periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome: clinical characteristics and outcome. J Pediatr 1999, 135:98–101.CrossRefPubMed

29.

Thomas KT, Feder HM Jr, Lawton AR, et al.: Periodic fever syndrome in children. J Pediatr 1999, 135:15–21.CrossRefPubMed

30.

Dagan E, Gershoni-Baruch R, Khatib I, et al.: MEFV, TNF1rA, CARD15 and NLRP3 mutation analysis in PFAPA. Rheumatol Int 2010, 30:633–636.CrossRefPubMed

31.

Stojanov S, Hoffmann F, Kery A, et al.: Cytokine profile in PFAPA syndrome suggests continuous inflammation and reduced anti-inflammatory response. Eur Cytokine Netw 2006, 17:90–97.PubMed

32.

Padeh S: Periodic fever syndromes. Pediatr Clin North Am 2005, 52:577–609.CrossRefPubMed

33.

Gattorno M, Caorsi R, Meini A, et al.: Differentiating PFAPA syndrome from monogenic periodic fevers. Pediatrics 2009, 124:e721–e728.CrossRefPubMed

34.

Tasher D, Somekh E, Dalal I: PFAPA syndrome: new clinical aspects disclosed. Arch Dis Child 2006, 91:981–984.CrossRefPubMed

35.

Pillet P, Ansoborlo S, Carrere A, et al.: (P)FAPA syndrome: value of cimetidine. Arch Pediatr 2000, 7:54–57.CrossRefPubMed

36.

Garavello W, Romagnoli M, Gaini RM: Effectiveness of adenotonsillectomy in PFAPA syndrome: a randomized study. J Pediatr 2009, 155:250–253.CrossRefPubMed

37.

Padeh S, Stoffman N, Berkun Y: Periodic fever accompanied by aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA syndrome) in adults. Isr Med Assoc J 2008, 10:358–360.PubMed

38.

Neven B, Callebaut I, Prieur AM, et al.: Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU. Blood 2004, 103:2809–2815.CrossRefPubMed

39.

• Goldbach-Mansky R, Kastner DL: Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J Allergy Clin Immunol 2009, 124:1141–1149. This is an exceptional review article that details the relationship between the inflammasome and IL-1.CrossRefPubMed

40.

Hawkins PN, Lachmann HJ, Aganna E, McDermott MF: Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004, 50:607–612.CrossRefPubMed

41.

Drenth JP, van der Meer JW: The inflammasome—a linebacker of innate defense. N Engl J Med 2006, 355:730–732.CrossRefPubMed

42.

Aksentijevich I, D Putnam C, Remmers EF, et al.: The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007, 56:1273–1285.CrossRefPubMed

43.

• Hoffman HM: Therapy of autoinflammatory syndromes. J Allergy Clin Immunol 2009, 124:1129–1138. This is an excellent article detailing the general approach to the treatment of autoinflammatory disorders, with a focus on newly approved therapies and novel approaches for the future.CrossRefPubMed

44.

• Ross JB, Finlayson LA, Klotz PJ, et al.: Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg 2008, 12:8–16. The authors very clearly highlight the role of anakinra in patients with FCAS, with follow-up at 4 and 16 months.PubMed

45.

Hawkins PN, Lachmann HJ, McDermott MF: Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003, 348:2583–2584.CrossRefPubMed

46.

Mirault T, Launay D, Cuisset L, et al.: Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum 2006, 54:1697–1700.CrossRefPubMed

47.

Goldbach-Mansky R, Dailey NJ, Canna SW, et al.: Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006, 355:581–592.CrossRefPubMed

48.

Hoffman HM, Throne ML, Amar NJ, et al.: Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008, 58:2443–2452.CrossRefPubMed

49.

• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al.: Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360:2416–2425. This paper demonstrated that treatment with subcutaneous canakinumab (an IL-1β monoclonal antibody) once every 8 weeks was associated with a rapid remission of symptoms in patients with CAPS.CrossRefPubMed

50.

Meng G, Strober W: New insights into the nature of autoinflammatory diseases from mice with Nlrp3 mutations. Eur J Immunol 2010, 40:649–653.CrossRefPubMed

Title: Periodic Fever Syndromes
Authors: Zachary Jacobs
Christina E. Ciaccio
Publication date: 01-11-2010
Publisher: Current Science Inc.
Published in: Current Allergy and Asthma Reports / Issue 6/2010
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-010-0141-z

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Periodic Fever Syndromes

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2010

Pediatric Pay-for-performance in Asthma: Who Pays?

The Hygiene Hypothesis Revisited: Role of Materno-Fetal Interactions

The Impact of Vaccination on Rhinosinusitis and Otitis Media

Molecular- and Flow Cytometry-based Diagnosis of Primary Immunodeficiency Disorders

Fetal Epigenetic Mechanisms and Innate Immunity in Asthma

Oseltamivir Treatment for Acute Otitis Media in Children with Influenza